China Reg Express: Anti-Blocking Law, Inspection Guideline And Gene Therapy Follow-Up Studies
Regs To Impact Businesses In And Outside China
A sweeping "anti-blocking" law, patent legislation, gene therapy study guidance and new regulations on inspections are all within a flurry of regulatory activity in China.
You may also be interested in...
In the latest sign that some multinationals are scaling down operations in the world's second-largest pharma market, Mundipharma is reported to be exploring the sale of its business in China, with a large group of bidders including state-owned Sinopharm and local private equity firm Boyu Capital in the running.
Facing a increasingly competitive environment and tense bilateral relationship, US biotechs must innovate and differentiate while protecting their innovations in China, say panelists at the BIO annual conference.
The Biden Administration’s pledge to provide 500 million doses of Pfizer/BioNTech's COVID-19 vaccines is a direct blow to China’s global vaccine diplomacy push.